|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 92 No. 11 (December 1), 1998:
pp. 4439-4445
Correction of the PNH Defect by GPI-Anchored Protein Transfer
By
Elaine M. Sloand,
Jaroslaw P. Maciejewski,
Daniel Dunn,
Joel Moss,
Bryan Brewer,
Martha Kirby, and
Neal S. Young
From the Hematology Branch, Pulmonary Critical Care Medicine Branch,
and Molecular Disease Branch, National Heart, Lung, and Blood
Institute, Bethesda, MD.
 |
ABSTRACT |
Hemolytic anemia is a major feature of paroxysmal nocturnal
hemoglobinuria (PNH). Intravascular red blood cell (RBC)
destruction is caused by increased sensitivity of the abnormal
erythrocyte to complement-mediated lysis, due to the GPI absence of a
membrane-bound glycosylphosphatidylinositol (GPI)-linked protein,
which functions as an inhibitor of reactive lysis (CD59). Both in vivo
and in vitro models have suggested the feasibility of cell-to-cell
transfer of GPI proteins, and patients with hemolysis could potentially benefit from transfer of CD59 to their deficient erythrocytes. We
studied the ability of RBC components prepared from outdated packed RBC
collections, as well as high-density lipoprotein (HDL) preparations,
rich in CD55 and CD59, to promote protein transfer, as assessed by flow
cytometry, immunoblotting, and susceptibility to complement-mediated
lysis. By flow cytometry, CD55 and CD59 were present on RBC-derived
microvesicles that stained with an antiglycophorin antibody Ab; in
addition, soluble CD59 and CD55 were detected by immunoblot in soluble
fractions eluated from RBC units stored for more than 35 days, but not
in fresh blood. Both commercial HDL preparations and those prepared in
our laboratory contained CD55 and CD59, as assayed by immunoblot. When
RBC that were deficient (GPI)-anchored protein, obtained from five
patients, with PNH were incubated with HDL preparations for 2 to 4 hours, there was significant transfer of both proteins to the cell
surface, as demonstrated by flow cytometry. Washed RBC microvesicles,
prepared by ultrasonification, also mediated transfer of GPI-linked
proteins to deficient RBC. Pretreatment of microvesicles, RBC eluate
preparations, and HDL with phosphatidylinositol-specific, phospholipase
C, abrogated protein transfer to deficient cells, indicating that
increased cell-associated CD55 and CD59 levels were related to
insertion of the intact GPI moiety, rather than to simple adhesion. PNH RBC that were exposed to HDL, RBC eluate preparations, or microvesicles demonstrated decreased in vitro complement-mediated hemolysis in the
Ham test. Transfer of GPI-linked proteins from soluble preparations
containing CD55 and CD59 to PNH erythrocytes is feasible and may have
clinical utility.
This is a US government work. There are no restrictions on its use.
| |
INTRODUCTION |
PAROXYSMAL NOCTURNAL hemoglobinuria (PNH)
is an acquired, clonal somatic stem cell disorder associated with
hemolysis, thrombosis, and bone marrow failure.1 PNH is
caused by somatic cell mutations in a gene called PIG-A that produces
global deficiency of a class of proteins linked to the cell surface by
a glycosylphosphatidylinositol (GPI) anchor.2,3 A large and
diverse group of GPI-anchored proteins have been described, some of
which have been clearly related to the pathophysiology of
PNH.4 Absence of CD59, an important inactivator of
complement present on the erythrocyte cell surface, results in the
exaggerated sensitivity of erythrocytes to complement-mediated lysis
(as measured in the Ham or sucrose hemolysis tests), intravascular
hemolysis, and often severe anemia.5,6
Cell-to-cell transfer of GPI-linked proteins has been demonstrated in a
mouse transgenic system,7 in "knock-out" embryonal bodies,8 and from trypanosomal membranes to red blood cells (RBC) of infected patients.9 High-density lipoproteins
(HDL) act as carriers of CD59 and are capable of transferring this
protein to erythrocytes.10 Data support the concept that
GPI-linked proteins also can be transferred to RBC in their intact form
(with retention of their ability to inactivate complement) by
prostosomes obtained from seminal fluid11 and from RBC to
endothelium in the transgenic mouse.7 Membrane-to-membrane
transfer by prostosomes can occur without actual membrane
fusion.11 In a different system, transfer of the GPI-linked
protein, CD59, occurred after incubation of a nonmembrane-associated,
protein-rich fraction with deficient cells.11 Retention of
an intact phospholipid tail appears to be necessary for the retention
of protein function, as soluble CD59, lacking its GPI anchor has only
1/200th the ability of GPI-linked CD59 to inactivate
complement.12
In the current study, we examined the effect of transfer of two
GPI-linked proteins, CD55 and CD59, on protection of deficient RBC
from hemolysis, using readily available sources of GPI-linked proteins,
HDL, and outdated RBC concentrates. Should function of transferred
protein be maintained, either could provide potential therapeutic
modalities for patients with PNH.
| |
MATERIALS AND METHODS |
Patient selection.
Informed consent was obtained according to a protocol approved by the
Institutional Review Board of the National Heart, Lung, and Blood
Institute. Samples of venous blood were obtained and analyzed from 20 healthy volunteers, 10 patients with PNH, and 7 patients with aplastic
anemia, not associated with PNH. PNH patients were identified based on
the results of the Ham test and clinical findings of hemolysis. The
diagnosis of aplastic anemia was established by bone marrow biopsy and
pancytopenia in accordance with the criteria of the International Study
of Aplastic Anemia and Agranulocytosis.
Flow cytometric analysis of RBC and RBC microvesicles.
RBC were incubated in the dark with monoclonal antibodies (MoAb)
directed to CD55 and CD59 (Monosan, Caltag, San Francisco, CA) and then
with fluorescein isothiocyanate (FITC)-conjugated or phycoerythrin
(PE)-conjugated goat (Fab) antimouse IgG. For phenotypic
identification, RBC were counterstained FITC-conjugated antiglycophorin
MoAb (Becton Dickinson, Mountain View, CA). Phycoerythrin- or
FITC-conjugated mouse isotype-matched MoAb served as controls (Becton
Dickinson). Samples were analyzed by forward and wide-angled light
scatter using a flow cytometer (FACScan; Becton Dickinson, San Jose,
CA). Based on the light scatter properties of platelet and RBC, a
region was drawn to include mostly erythrocytes and 1 × 104 events were collected. Binding of FITC-conjugated MoAb
to RBC or RBC-derived microparticles was expressed as mean channel
fluorescence (MCF) intensity or as a percentage of the particles
binding MoAb. RBC-derived microvesicles reacting with antiglycophorin
antibody were examined and distinguished from intact erythrocytes on
the basis of size (light scatter) and from cellular debris.
Microvesicles were washed with phosphate-buffered saline (PBS) and
incubated with MoAb as described above.
Preparation of RBC eluate and microvesicles enriched for CD55 and
CD59.
For preparation of RBC eluates, AB-negative units of packed RBC stored
at 4°C for 35 days under standard transfusion practice conditions were washed once with 50 mL of PBS. The wash solution was
filtered using a 100-kD filter to remove microvesicles and membrane fragments. The filtrate was concentrated using a 10-kD filter
and complement inactivated by heating to 50°C for 30 minutes. Microvesicles were obtained from stored RBC by sonication for 10 seconds at 4°C and then separated from intact erythrocytes by
differential centrifugation, followed by five cycles of washing in PBS.
Transfer of GPI-anchored proteins to deficient RBC.
Complement-inactivated RBC eluates prepared as detailed above,
microvesicles, or HDL was added to GPI-anchored protein-deficient RBC
from PNH patients or to erythrocytes from Rhesus monkeys (which do not
cross-react with antihuman CD55 or CD59 MoAb). Samples were incubated
with individual preparations for 2 hours, washed with PBS, and prepared
for flow cytometry as described above.
Ham test.
A standard Ham test was performed, as previously described, using
acidified AB negative sera as a source of activated
complement.13 The increase in soluble hemoglobin after the
reaction with activated complement was expressed as a percentage of the
total hemoglobin content of the cell preparation (  540 nm).
Western blot analysis.
RBC eluates, microvesicles, and HDL preparations were used for
immunoblotting. Before immunoblotting, HDL preparations were filtered
through a 100-kD filter. Protein preparations were electrophoresed in
14% of sodium dodecyl sulfate (SDS)-polyacrylamide gels, which were
then equilibrated in transfer buffer (125 mmol/L TRIS
[2-amino-2(hydroxymethyl-1,3 propanediol)]-base, 960 mmol/L glycine,
20% methanol), and separated proteins were electrophoretically
transferred on polyvinylidene difluoride (PVDF) membranes
(Immobilon-P Millipore, Bedford, MA). Membranes were blocked in
TBST-milk (10 mmol/L TRIS-HCI [pH 8.0], 150 mmol/L NaCl, 0.5%
Tween-20, 1% nonfat dry milk, 1% bovine serum albumin [Cohn fraction
V; Miles, Kankakee, IL]) and treated with either CD55 or CD59 MoAb.
Samples were incubated with goat anti-IgG after washing and then
subsequently with goat antialkaline phosphatase MoAb (Dako,
Carpinteria, CA). Specific bands were detected using nitroblue
tetrazolium (NBT)/5-bromo-4 chloro-3-indolyl phosphate (BCIP) substrate
(Pierce, Rockford, IL).
| |
RESULTS |
Production of cell-free CD55 and CD59.
We first attempted to determine if storage of RBC under blood banking
conditions resulted in the loss of GPI-linked proteins by shedding of
either soluble CD55 and CD59 into solution or by formation of
microvesicles containing CD55 and CD59. After the addition of PBS to
stored RBC, intact RBC were removed by centrifugation at 1,000g
and supernatant was analyzed for microvesicles. Microvesicles were
gated by the flow cytometer to include particles that stained with
antiglycophorin MoAb and were smaller than RBC; most such particles in
the wash solution also stained with both CD55 and CD59 antibodies
(Fig 1A) (n = 6). Few if any of these
microvesicles were detected in fresh RBC preparations (data not shown).
When the RBC eluate was filtered using a 100-kD filter to remove
microvesicles and membrane fragments and further subjected to a 3-kD
filter, soluble CD59 and CD55 antigens at 19 kD and 60 kD,
respectively, were present on immunoblot, after staining with CD59 and
CD55 MoAb (Fig 1B and C) (n = 10). Western blot of HDL concentrates (prepared in our laboratory or obtained commercially [Athens Research & Technology, Athens, GA; Biomedical Technologies, Stoughton, MA; or
Fluka Chemical Corp, Ronkonkoma, NY]) also demonstrated bands of
molecular weights corresponding to those of human CD55 (Fig 1B) and
CD59 glycoproteins (Fig 1, D) (n = 10).
View larger version (42K):
[in this window]
[in a new window]
| Fig 1.
(A) Flow cytometric analysis of RBC microvesicles shed
from stored RBC. Two units of packed RBC units, stored for 35 days at
4°C, were washed with PBS. RBC microvesicles were gated by forward
scatter/side scatter to include microparticles, smaller than RBCs,
staining with antiglycophorin; scattergrams with gates can be seen on
the right. Gated microvesicles of the two units (above and below)
stained with CD59 and antiglycophorin are demonstrated on the left. (B
and C) Immunoblot of RBC eluate, microvesicles, and HDL. Samples of RBC
eluates (1), microvesicles (2), and HDL (3) were solubilized with 3%
SDS and analyzed by immunoblot (on 12% polyacrylamide gel) with CD55
(B), CD59 (C) MoAbs. Bands at 19 (B) and 60 kD (C) correspond to CD59
and CD55, respectively. (D) Immunoblots of four commercial HDL
preparations (labeled 1 through 4) stained with CD59 MoAb (on 14%
polyacylamide gel). A band at 19 kD corresponds to CD59.
|
|
Transfer of CD55 and CD59 to deficient RBC.
We next determined if GPI-anchored proteins could be transferred to
GPI-protein-deficient RBC, using RBC eluates, microvesicles, or HDL.
When CD55 and CD59-deficient erythrocytes of patients with PNH (n = 5)
or simian RBC (n = 15) (which lack proteins cross-reactive with human
CD55 and CD59 antigens) were incubated with complement-inactivated RBC
eluates (n = 7), microvesicles (n = 6), or HDL (n = 11), both types of
target cells showed increased cell surface membrane content of CD59
(Fig 2) and CD55
(Fig 3); example of microvesicle transfer is seen in Fig 4. Composite rhesus data on
HDL transfer is seen in Fig 5. When
deficient PNH patient samples were treated with HDL (n = 5), there was
an average increase of 20% in the number of cells expressing CD59 and
10% in CD55 (five patients, 13 HDL preparations). Transfer of CD55 and
CD59 after treatment with RBC eluates varied greatly depending on the
RBC eluate preparation used; efficiency of transfer appeared to be
related to the concentration of CD55 and CD59 in the preparation as
determined by immunoblot; this dose dependence is demonstrated in
Fig 6; an intact phospholipid anchor
appeared to be necessary for transfer, as pretreatment of HDL, RBC
eluate, and microvesicles with
phosphotidylinositol-specific-phospholipase C (PI-PLC)
eliminated transfer (Fig 2).
View larger version (34K):
[in this window]
[in a new window]
| Fig 2.
Transfer of CD59 from RBC eluates (A) and HDL (B) to
monkey RBC lacking cross reactive CD59 antigen. Monkey RBC was washed
in PBS, incubated with RBC eluate or HDL for 1 hour at 37°C, then
subsequently washed and stained with CD59-FITC. PI-PLC (1 U/mL) for 1 hour at 37°C treatment of samples of RBC eluate and HDL
significantly decreased transfer.
|
|
View larger version (28K):
[in this window]
[in a new window]
| Fig 3.
Transfer of CD55 to PNH cells and to monkey cells by RBC
eluate (A) and HDL (B) after 1 hour of incubation. Procedures are as
described above in Fig 2.
|
|
View larger version (19K):
[in this window]
[in a new window]
| Fig 4.
Deficient monkey RBCs were incubated with RBC
microvesicles for 2 hours. Treated cells were then washed
with PBS and stained with CD55-PE and CD59-FITC.
|
|
View larger version (12K):
[in this window]
[in a new window]
| Fig 5.
Transfer of CD55 and CD59 to monkey erythrocyes by HDL
preparations (n = 11). After a 2-hour incubation at 37°C, cells
were stained using CD55-FITC or CD59-FITC and analyzed by flow
cytometry. Untreated samples are indicated by ( ), treated as
( ).
|
|
View larger version (30K):
[in this window]
[in a new window]
| Fig 6.
Dose-dependent transfer of CD59 from RBC eluate (A) and
HDL (B). Increasing concentrations, (denoted as 1X, 2X) of RBC eluate
or HDL were incubated with PNH cells. RBC were washed and stained with
CD59-FITC. Scattergrams of RBCs treated with RBC eluate (A) HDL (B) are
seen above.
|
|
Restoration of functional properties of reconstituted cells.
To examine the functional consequences of transfer of GPI-linked
proteins, we tested the effect of CD59 transfer on complement-mediated lysis of erythrocytes derived from PNH patients, as measured in the Ham
test. Treatment of PNH RBC with eluate or HDL conferred relative
resistance to complement-mediated lysis, as evidenced by a significant
decrease in hemolysis in the Ham test (example seen in
Fig 7).
View larger version (20K):
[in this window]
[in a new window]
| Fig 7.
Ham test of RBC treated RBC. Samples of PNH RBC were
incubated for 1 hour with RBC eluate, HDL, or microvesicles at
37°C, washed with PBS, and incubated with acidified serum as a
source of complement. Optical density measurements at 540 nm are shown on the right. Histograms of corresponding samples stained
with CD59-FITC are seen at the left. CD55 expression was greater on the
RBC incubated with HDL than on those incubated with RBC eluate (data
not shown). Untreated samples showed 30% hemolysis, HDL treated 7%,
RBC eluate treated 15%.
|
|
| |
DISCUSSION |
Cell-to-cell transfer of GPI-linked protein transfer has been reported
in a variety of systems. In the first report, the variable surface
glycoprotein (VSG),14 which is attached to trypanosomes through a GPI-anchor, was transferred to the human erythrocyte by
coincubation. Human CD59, expressed by transgenic mouse erythrocytes, could also be transferred to the intact mouse vascular endothelial cells.7 In our laboratory, we have shown transfer of CD24
from normal embryonic stem cells (ESC) to a PIG-A
(GPIAP) knock-out
ESC.8 Embryoid bodies composed only of
PIG-A cells did not form hematopoietic colonies, but
chimeric bodies containing
GPIAP+ ECS exhibited
PIG-A knock-out-derived hematopoiesis.
In the current study, we demonstrate that RBC eluates and microvesicles
prepared from outdated RBC concentrates, as well as HDL, contain CD55
and CD59 and can transfer both GPI-linked proteins to deficient RBC.
Transferred CD59 appears to be functional, as it is capable of
inhibiting hemolysis in susceptible cells. Successful transfer of both
CD55 and CD59 was dependent on the presence of an intact GPI-anchor, as
cleavage of that anchor by PI-specific phospholipase C decreased the
efficiency of transfer as determined by flow cytometry. Although
investigators have previously shown that HDL acts as a carrier of
GPI-linked CD5910 and is capable of transferring the
protein from RBC to RBC and from RBC to endothelium, they never
demonstrated retention of function of protein after transfer. HDL has
also not previously been reported to act as a carrier for CD55.
The Ham test, broadly, correlated with the flow cytometry data; the Ham
test showed differences in RBC eluate and HDL hemolysis, despite
similar CD59 expression (but greater CD55 expression) measured by flow
cytometry. This discordance may be explained by the fact that only
major differences in CD59 and CD55 expression are detected by flow
cytometry. Small differences in transfer may be reflected in large
differences in sensitivity to hemolysis. It may also be possible that
additional proteins (including CD55), capable of conferring resistance
to acidified complement in vitro, are present (and transferred) in the
HDL preparations but not in eluates. The amount of GPI-linked protein
expression required to prevent hemolysis is also unclear and the
pathophysiology of hemolysis may be complex. Lysis of cells during
incubation with GPI-rich preparations cannot be excluded in samples of
PNH cells in which transfer was performed. However, each HDL and RBC
eluate preparation underwent heat treatment to inactivate complement, and RBC numbers were similar before and after incubation.
The amount of transfer was dependent on the length of incubation and
the concentration of the transferring protein. Histograms showing a
phenotype intermediate between normal and abnormal could be seen in
samples exposed to lesser concentrations for shorter times. The figures
chosen for this report show only samples exposed for optimal times and
concentrations to demonstrate optimal transfer. The absence of linear
transfer in some instances may be related to the complexities involved
in protein and lipid transfer. GPI-linked proteins may be located
within caveolae structures and delivery of the GPI-linked protein to
the membrane structure may be related to multiple factors, which allow
fusion of this structure to the membrane. Alternatively, initial
membrane acquisition of GPI-linked proteins may affect the probability
of subsequent transfer events.
It is not surprising that outdated RBC stored for transfusion contain
material rich in GPI-linked proteins. Long et al15 reported
loss of both CD55 and CD59 from the RBC membrane during a 6-week
storage. RBC microvesicles are formed during RBC storage and a number
of investigators16 have demonstrated enrichment of
microvesicles in GPI-linked proteins including CD55 and CD59.
Cell-to-cell transfer or reuptake of proteins from shed membrane
fragments of RBC or from membrane-free proteins, which probably exist
in the form of micelles, are all potential avenues of transfer of
GPI-linked proteins. Both HDL and RBC eluates could potentially provide
convenient vehicles for protein transfer to deficient cells and either
could provide successful therapeutic interventions for patients with
PNH and incapacitating hemolysis. We have shown convincing in vitro
evidence that hemolysis of PNH cells is inhibited by transfer. Previous
data demonstrating that PNH cells expressing subnormal amounts of CD59
have prolonged in vivo survival compared with PNH cells expressing no
protein,17 suggests that even partial transfer of protein
may have real clinical consequences. Whether significant transfer
occurs in vivo between RBC lacking GPI-linked proteins and those
expressing them is unknown and is currently being investigated.
Transfer of GPI-linked proteins in vivo is supported by the fact that
flow cytometry examination of cells from PNH patients rarely shows two
discrete populations of cells. Often a substantial population of cells
with CD55 and CD59 expression that is intermediate between normal and
negative cells can be detected. Even in the presence of a nonsense
mutation, totally eliminating functional expression of PIG-A proteins,
affected cell clones would be expected to exhibit GPI expression
intermediate between normal and negative cells if transfer occurred.
Furthermore, one group of investigators reported that although
reticulocytes of a group of PNH patients were almost all GPI-deficient,
most cases demonstrated a significant population of RBC exhibiting GPI-linked proteins intermediate between normal and deficient (type II
cells).18
Transfusions of normal RBC to PNH patients may provide a source of
GPI-enriched proteins to the deficient cells and could potentially lead
to increased survival of PNH cells if significant transfer from
transfused cells to PNH cells occurred. An advantage of cell-free
GPI-rich preparation is that protein solutions can potentially be made
infection-free by filtration and heat sterilization and do not result
in iron-overload. A number of factors including albumin concentration,
temperature, and salt concentration may affect transfer in
vitro,18 and it is difficult to predict what conditions
would pertain in vivo.
Our study was designed to determine if GPI-linked proteins could be
transferred from HDL and from RBC eluates and microvesicles obtained
from outdated RBC units stored for transfusion. The feasibility of
using these modes of transfer may have important consequences for
therapy of PNH, as well as to understanding of the pathophysiology of
the disease.
| |
FOOTNOTES |
Submitted January 8, 1998;
accepted July 16, 1998.
The publication costs of this
article were defrayed in part by
page charge payment. This article
must therefore be hereby marked
"advertisement"
in accordance with 18 U.S.C. section
1734 solely to indicate this fact.
This is a US government work. There are no restrictions on its use.
Address reprint requests to Elaine M. Sloand, MD, 31 Center Dr, MSC
2490, Bldg 31, Room 4A11, Bethesda, MD 20892-2490.
| |
REFERENCES |
1.
Rosse WF, Ware RE:
The molecular basis of paroxysmal nocturnal hemoglo binuria.
Blood
86:3277, 1995[Free Full Text]
2.
Takeda J, Miyata T, Kawagoe K, Iida Y, Endo Y, Fujita T, Takahashi M, Kitani T, Kinoshita T:
Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria.
Cell
73:703, 1993[Medline]
[Order article via Infotrieve]
3.
Bessler M, Mason P, Hillmen P, Luzzatto L:
Somatic mutations and cellular selection in paroxysmal nocturnal hemoglobinuria.
Lancet
343:951, 1994[Medline]
[Order article via Infotrieve]
4.
Rosse WF:
Phosphatidylinositol-linked proteins and paroxysmal nocturnal hemoglobinuria.
Blood
75:1595, 1990[Free Full Text]
5.
Wilcox LA, Ezzell JL, Bernshaw NJ, Parker CJ:
Molecular basis of the enhanced susceptibility of the erythrocytes of paroxysmal nocturnal hemoglobinuria to hemolysis in acidified serum.
Blood
78:820, 1991[Abstract/Free Full Text]
6.
Meri S, Lehto T, Sutton CW, Tynela J, Bauman M:
Structural composition and functional characterization of soluble CD59: Heterogeneity of the oligosaccharide and glycophosphoinositol (GPI) anchor revealed by laser-desorption mass spectrometric analysis.
Biochem J
316:923, 1996
7.
Kooyman DL, Byrne GW, McClellan S, Nielsen D, Tone M, Waldmann H, Coffman TM, McCurry KR, Platt JL, Logan JS:
In vivo transfer of GPI-linked complement restriction factors from erythrocytes to the endothelium.
Science
269:89, 1995[Abstract/Free Full Text]
8.
Dunn DE, Yu J, Nagarajan S, Devetten M, Weichold FF, Medof ME, Young NS, Liu JM:
A knock-out model of paroxysmal nocturnal hemoglobinuria: PIG-A hematopoiesis is reconstituted following intercellular transfer of GPI-anchored proteins.
Proc Natl Acad Sci USA
93:7938, 1996[Abstract/Free Full Text]
9.
Rifkin MR, Landsberger FR:
Trypanosome variant surface glycoprotein transfer to target membranes: A model for the pathogenesis of trypanosomiasis.
Proc Natl Acad Sci USA
87:801, 1990[Abstract/Free Full Text]
10.
Vakeva A, Jauhiainen M, Ehnholm C, Lehto T, Meri S:
High-density lipoproteins can act as carriers of glycophosphoinositol lipid-anchored CD59 in human plasma.
Immunology
82:28, 1994[Medline]
[Order article via Infotrieve]
11.
Rooney IA, Heuser JE, Atkinson JP:
GPI-anchored complement regulatory proteins in seminal plasma. An analysis of their physical condition and the mechanisms of their binding to exogenous cells.
J Clin Invest
97:1675, 1996[Medline]
[Order article via Infotrieve]
12.
Walter EI, Ratnoff WD, Long KE, Kazura JW, Medof ME:
Effect of glycoinositolphospholipid anchor lipid groups on functional properties of decay-accelerating factor protein in cells.
J Biol Chem
267:1245, 1992[Abstract/Free Full Text]
13.
Rosse WF:
Dr. Ham's test revisited.
Blood
78:547, 1991[Free Full Text]
14.
Pearce EJ, Hall BF, Sher A:
Post-specific evasion of the alternative complement pathway by schistosomes correlates with the presence of a phospholipase C-sensitive surface molecule resembling human decay accelerating factor.
J Immunol
144:2751, 1990[Abstract]
15.
Long KE, Yomtovian R, Kida M, Knez JJ, Medof ME:
Time-dependent loss of surface complement regulatory activity during storage of donor blood.
Transfusion
33:294, 1993[Medline]
[Order article via Infotrieve]
16.
Butikofer P, Kuypers FA, Xu CM, Chiu DTY, Lubin B:
Enrichment of two glycosyl-phosphatidylinositol-anchored proteins, acetylcholinesterase and decay accelerating factor, in vesicles released from human red blood cells.
Blood
74:1481, 1989[Abstract/Free Full Text]
17.
Fujioka S, Yamada T:
Longer in vivo survival of CD59- and decay-accelerating factor-almost normal positive and partly positive erythrocytes in paroxysmal nocturnal hemoglobinuria as compared with negative erythrocytes: A demonstration by differential centrifugation and flow cytometry.
Blood
79:1842, 1992[Abstract/Free Full Text]
18.
Ware RE, Rosse WF, Hall SE:
Immunophenotypic analysis of reticulocytes in paroxysmal nocturnal hemaoglobinuria.
Blood
86:1586, 1995[Abstract/Free Full Text]
This is a US government work. There are no restrictions on its use.
0006-4971/98/9211-0040$0.00/0
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
E. M. Pasini, M. Kirkegaard, D. Salerno, P. Mortensen, M. Mann, and A. W. Thomas
Deep Coverage Mouse Red Blood Cell Proteome: A First Comparison with the Human Red Blood Cell
Mol. Cell. Proteomics,
July 1, 2008;
7(7):
1317 - 1330.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. S Griffiths, K. A Miller, D. S Galileo, and P. A Martin-DeLeon
Murine SPAM1 is secreted by the estrous uterus and oviduct in a form that can bind to sperm during capacitation: acquisition enhances hyaluronic acid-binding ability and cumulus dispersal efficiency
Reproduction,
March 1, 2008;
135(3):
293 - 301.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. M. Pasini, M. Kirkegaard, P. Mortensen, H. U. Lutz, A. W. Thomas, and M. Mann
In-depth analysis of the membrane and cytosolic proteome of red blood cells
Blood,
August 1, 2006;
108(3):
791 - 801.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Hill, S. H. Ridley, D. Esser, R. G. Oldroyd, M. J. Cullen, P. Kareclas, S. Gallagher, G. P. Smith, S. J. Richards, J. White, et al.
Protection of erythrocytes from human complement-mediated lysis by membrane-targeted recombinant soluble CD59: a new approach to PNH therapy
Blood,
March 1, 2006;
107(5):
2131 - 2137.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. M. Sloand, L. Mainwaring, K. Keyvanfar, J. Chen, J. Maciejewski, H. G. Klein, and N. S. Young
Transfer of glycosylphosphatidylinositol-anchored proteins to deficient cells after erythrocyte transfusion in paroxysmal nocturnal hemoglobinuria
Blood,
December 1, 2004;
104(12):
3782 - 3788.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Mortazavi, B. Merk, J. McIntosh, J. C. W. Marsh, H. Schrezenmeier, and T. R. Rutherford
The spectrum of PIG-A gene mutations in aplastic anemia/paroxysmal nocturnal hemoglobinuria (AA/PNH): a high incidence of multiple mutations and evidence of a mutational hot spot
Blood,
April 1, 2003;
101(7):
2833 - 2841.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-i. Nishimura, K. L. Phillips, R. E. Ware, S. Hall, L. Wilson, T. L. Gentry, T. A. Howard, Y. Murakami, M. Shibano, T. Machii, et al.
Efficient retrovirus-mediated PIG-A gene transfer and stable restoration of GPI-anchored protein expression in cells with the PNH phenotype
Blood,
May 15, 2001;
97(10):
3004 - 3010.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Artl, G. Marsche, S. Lestavel, W. Sattler, and E. Malle
Role of Serum Amyloid A During Metabolism of Acute-Phase HDL by Macrophages
Arterioscler. Thromb. Vasc. Biol.,
March 1, 2000;
20(3):
763 - 772.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Butikofer;, E. Sloand, J. Maciejewski, D. Dunn, J. Moss, and N. Young
Correction of the PNH defect by GPI protein transfer: still an open question
Blood,
March 1, 2000;
95(5):
1876 - 1877.
[Full Text]
[PDF]
|
|
|
|
|
Top
Abstract
Introduction